Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81

Haemonetics Corporation (NYSE:HAE) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81 Haemonetics Corporation (NYSE:HAE) is among the most innovative healthcare stocks. TheFly reported on February 6 that Baird lowered its price target for HAE to $81 from $99 while maintaining an Outperform rating. The firm updated its model following the company’s Q3 results and lowered the estimate ...